{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T15:50:54Z","timestamp":1788364254549,"version":"build-2803163510"},"reference-count":15,"publisher":"Japanese Society of Internal Medicine","issue":"20","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2024,10,15]]},"DOI":"10.2169\/internalmedicine.3113-23","type":"journal-article","created":{"date-parts":[[2024,3,10]],"date-time":"2024-03-10T22:13:53Z","timestamp":1710108833000},"page":"2839-2845","source":"Crossref","is-referenced-by-count":3,"title":["Pegylated-liposomal Doxorubicin-induced Glomerular Thrombotic Microangiopathy"],"prefix":"10.2169","volume":"63","author":[{"given":"Shingo","family":"Yokoyama","sequence":"first","affiliation":[{"name":"The Second Department of Internal Medicine, University of Toyama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kota","family":"Kakeshita","sequence":"additional","affiliation":[{"name":"The Second Department of Internal Medicine, University of Toyama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teruhiko","family":"Imamura","sequence":"additional","affiliation":[{"name":"The Second Department of Internal Medicine, University of Toyama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoko","family":"Shima","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, University of Toyama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayato","family":"Fujioka","sequence":"additional","affiliation":[{"name":"The Second Department of Internal Medicine, University of Toyama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidenori","family":"Yamazaki","sequence":"additional","affiliation":[{"name":"The Second Department of Internal Medicine, University of Toyama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsutomu","family":"Koike","sequence":"additional","affiliation":[{"name":"The Second Department of Internal Medicine, University of Toyama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichiro","family":"Kinugawa","sequence":"additional","affiliation":[{"name":"The Second Department of Internal Medicine, University of Toyama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Singal PK, Iliskovic N. Doxorubicin-induced cardiomyopathy. N Engl J Med 339: 900-905, 1998.","DOI":"10.1056\/NEJM199809243391307"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. O&apos;Brien ME, Wigler N, Inbar M, et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX\u2122\/Doxil<sup>\u00ae<\/sup>) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol 15: 440-449, 2004.","DOI":"10.1093\/annonc\/mdh097"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Kwa M, Baumgartner R, Shavit L, et al. Is renal thrombotic angiopathy an emerging problem in the treatment of ovarian cancer recurrences? Oncologist 17: 1534-1540, 2012.","DOI":"10.1634\/theoncologist.2011-0422"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. George JN, Nester CM. Syndromes of thrombotic microangiopathy. N Engl J Med 371: 654-666, 2014.","DOI":"10.1056\/NEJMra1312353"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Genest DS, Patriquin CJ, Licht C, John R, Reich HN. Renal thrombotic microangiopathy: a review. Am J Kidney Dis 81: 591-605, 2023.","DOI":"10.1053\/j.ajkd.2022.10.014"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Lee VW, Harris DC. Adriamycin nephropathy: a model of focal segmental glomerulosclerosis. Nephrology (Carlton) 16: 30-38, 2011.","DOI":"10.1111\/j.1440-1797.2010.01383.x"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Mohamed N, Goldstein J, Schiff J, John R. Collapsing glomerulopathy following anthracycline therapy. Am J Kidney Dis 61: 778-781, 2013.","DOI":"10.1053\/j.ajkd.2012.08.048"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Carron PL, Padilla M, Maurizi Balzan J. Nephrotic syndrome and acute renal failure during pegylated liposomal doxorubicin treatment. Hemodial Int 18: 846-847, 2014.","DOI":"10.1111\/hdi.12196"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Savani M, Woerner K, Bu L, Birkenbach M, Skubitz KM. Pegylated liposomal doxorubicin-induced renal toxicity in retroperitoneal liposarcoma: a case report and literature review. Cancer Chemother Pharmacol 87: 289-294, 2021.","DOI":"10.1007\/s00280-020-04203-z"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Rodriguez-Ramirez S, Yau K, Kitchlu A, et al. Pegylated liposomal doxorubicin and kidney-limited thrombotic microangiopathy in a kidney transplant recipient: a case report. Kidney Med 4: 100461, 2022.","DOI":"10.1016\/j.xkme.2022.100461"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Guo J, Ananthakrishnan R, Qu W, et al. RAGE mediates podocyte injury in adriamycin-induced glomerulosclerosis. J Am Soc Nephrol 19: 961-972, 2008.","DOI":"10.1681\/ASN.2007101109"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Podyacheva E, Danilchuk M, Toropova Y. Molecular mechanisms of endothelial remodeling under doxorubicin treatment. Biomed Pharmacother 162: 114576, 2023.","DOI":"10.1016\/j.biopha.2023.114576"},{"key":"13","unstructured":"13. Yuan F, Leunig M, Huang SK, Berk DA, Papahadjopoulos D, Jain RK. Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft. Cancer Res 54: 3352-3356, 1994."},{"key":"14","doi-asserted-by":"publisher","unstructured":"14. Oros-Pantoja R, C\u00f3rdoba-Adaya JC, Torres-Garc\u00eda E, et al. Preclinical evaluation of early multi-organ toxicity induced by liposomal doxorubicin using <sup>67<\/sup>Ga-citrate. Nanotoxicology 16: 247-264, 2022.","DOI":"10.1080\/17435390.2022.2071180"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Mohamed M, Abu Lila AS, Shimizu T, et al. PEGylated liposomes: immunological responses. Sci Technol Adv Mater 20: 710-724, 2019.","DOI":"10.1080\/14686996.2019.1627174"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/63\/20\/63_3113-23\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,19]],"date-time":"2024-10-19T03:27:23Z","timestamp":1729308443000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/63\/20\/63_3113-23\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,15]]},"references-count":15,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.3113-23","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,15]]},"article-number":"3113-23"}}